Clinical Trials
Last Updated July 9, 2020
Below is a list of clinical trials being conducted by the UCCRI at St. Joseph's Healthcare Hamilton. The study name, description, enrolment status is provided, along with the name and extension of the coordinator managing the research. To contact a research coordinator, call 905-522-1155 (St. Joe's main line) followed by the extension.
Jump to:
The UCCRI is based at St. Joe's, with physicians across the Hamilton area. For a list of genitourinary and renal clinical trials at the Juravinski Cancer Centre, click here.
Due to COVID-19, enrolment of these trials may be impacted.
Renal Trials
| Study Name | Description | Status | Contact |
| CLEAR | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR) | Enrolment Closed |
Liz x35214 |
| PAPMET/REC.3 | A Randomized, Phase ll Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib in Metastatic Papillary Renal Carcinoma | Enrolment Closed |
Camilla x35876 |
| PROSPER/REC.4 |
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) |
Open |
Camilla x35876 |
| SBRT vs. RFA (RADSTER) |
A Prospective Randomized Pilot Trial of Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for the Management of Small Renal Masses |
Open |
Camilla x35876 |
Bladder
| Study Name | Description | Status | Contact |
| MERCK KEYNOTE-676 | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676) | Not Open Yet |
Simreet x35812 |
| TACT | Tranexamic Acid during Cystectomy Trial (TACT) | Open |
Simreet x35812 |
Prostate
| Study Name | Description | Status | Contact |
| MAGNITUDE |
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer |
Open |
Simreet x35812 |
|
MYOVANT - HERO |
A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer |
Enrolment Closed |
Simreet x35812 |
|
MAST STUDY |
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study | Not Enrolling |
Liz x35214 |
|
ARN - SPARTAN |
A Multicentre, Randomized, Double-blind, Phase III study of ARN-509 in men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer |
Enrolment Closed |
Liz x35214 |
|
MEDIVATION -PROSPER STUDY |
A Mutlinational, Phase 3, Randomized, Double blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Non-metastatic Castrate Resistant Prostate Cancer | Enrolment Closed |
Liz x35214 |
| LATITUDE |
A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) |
Enrolment Closed |
Liz x35214 |
|
TITAN |
A Phase 3 Randomized, placebo controlled, Double Blind study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low- Volume Metastatic Hormone Sensitive Prostate Cancer (mHSPC) |
Enrolment Closed |
Liz x35214 |
|
PIC’s Study |
Advanced Prostate Imaging of Recurrent Cancer after Radiotherapy (PICs) |
Enrolment Closed |
Liz x35214 |
|
PEACE III |
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. |
Not Open Yet |
Shavy x37353 |
|
CRONOS II |
Canadian Real Life Evaluation of the Effect of Diet and Exercise in Prostate Cancer Patients Managed with Lupron | Enrolment Closed |
Camilla x35876 |
| GURC Cohort Study |
A Multicentre Cohort Study of Patients with Advanced Prostate Cancer in Canada |
Open |
Simreet x35812 |
| PREP Study |
PSMA-PET Registry for Recurrent Prostate Cancer |
Open |
Camilla x35876 |